RTW Investments, LP
13F filer · CIK 0001493215Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$11.7BU.S. long equity reported on 13F
Positions849 new · 13 closed
Net flow last quarter-$82MBuys minus sells
Top 10 positions weight47.7%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202684 positions | |||||
| $1.07B | 9.14% | 8.63% | Not reported | Q2 2023 | |
| $658M | 5.62% | 1.15% | Not reported | Q2 2017 | |
| $632M | 5.39% | 9.30% | Not reported | Q4 2016 | |
| $620M | 5.30% | 7.83% | 0.0% | Q3 2019 | |
| $605M | 5.16% | 9.64% | +21.9% | Q1 2024 | |
| $516M | 4.41% | 2.22% | Not reported | Q2 2023 | |
| $435M | 3.71% | 8.26% | +4.5% | Q3 2021 | |
| $377M | 3.22% | 4.83% | +1.9% | Q4 2023 | |
| $346M | 2.95% | 6.76% | +8.7% | Q4 2025 | |
| $329M | 2.81% | 5.74% | +11.1% | Q4 2025 | |
| $299M | 2.55% | 6.16% | +13.1% | Q4 2023 | |
| $299M | 2.55% | 5.14% | +52.5% | Q3 2024 | |
| $271M | 2.32% | 0.70% | -20.0% | Q3 2015 | |
| $260M | 2.22% | 7.91% | +113.7% | Q4 2021 | |
| $260M | 2.22% | 6.63% | +30.8% | Q4 2025 | |
| $244M | 2.08% | 2.30% | +5.2% | Q3 2020 | |
| $237M | 2.03% | 8.31% | New | Q2 2026 | |
| $228M | 1.95% | 8.91% | Not reported | Q3 2018 | |
| $222M | 1.90% | 1.11% | Not reported | Q3 2020 | |
| $214M | 1.82% | 1.25% | +19.4% | Q2 2025 | |
| $211M | 1.80% | 7.76% | +0.3% | Q4 2020 | |
| $184M | 1.57% | 9.01% | Not reported | Q2 2019 | |
| $182M | 1.55% | 5.68% | +52.4% | Q4 2017 | |
| $181M | 1.54% | 4.15% | Not reported | Q2 2022 | |
| $169M | 1.45% | 2.20% | +2.9% | Q4 2025 | |
| $167M | 1.43% | 9.30% | Not reported | Q3 2021 | |
| $160M | 1.36% | 9.57% | Not reported | Q2 2021 | |
| $155M | 1.32% | 9.46% | Not reported | Q1 2021 | |
| $151M | 1.29% | 7.88% | +0.7% | Q4 2024 | |
| $131M | 1.12% | 9.66% | +0.6% | Q3 2020 | |
| $125M | 1.07% | 0.59% | Not reported | Q4 2024 | |
| $122M | 1.05% | 1.54% | Not reported | Q4 2019 | |
| $110M | 0.94% | 1.82% | Not reported | Q3 2025 | |
| $109M | 0.93% | 9.12% | Not reported | Q3 2024 | |
| $92.3M | 0.79% | 4.17% | -0.9% | Q3 2023 | |
| $89.4M | 0.76% | 1.35% | -57.7% | Q3 2025 | |
| $87.6M | 0.75% | 1.00% | Not reported | Q3 2023 | |
| $86.3M | 0.74% | 0.75% | Not reported | Q2 2024 | |
| $82M | 0.70% | 8.83% | +0.7% | Q2 2024 | |
| $66.3M | 0.57% | 9.11% | +0.7% | Q3 2019 | |
| $66.1M | 0.56% | 8.44% | Not reported | Q1 2026 | |
| $60.5M | 0.52% | 16.15% | Not reported | Q1 2018 | |
| $58M | 0.49% | 2.37% | Not reported | Q4 2025 | |
| $51.3M | 0.44% | 2.98% | Not reported | Q1 2026 | |
| $46.7M | 0.40% | 1.89% | New | Q2 2026 | |
| $43.8M | 0.37% | 0.03% | Not reported | Q4 2023 | |
| $43.1M | 0.37% | 3.67% | +38.6% | Q2 2024 | |
| $42.8M | 0.37% | 8.61% | Not reported | Q1 2024 | |
| $41.5M | 0.35% | 3.05% | -74.1% | Q4 2025 | |
| $41.2M | 0.35% | 15.90% | +15.1% | Q1 2023 | |
| Q1 2026Reported May 15, 202688 positions | |||||
| $1.04B | 10.38% | 8.65% | Not reported | Q2 2023 | |
| $792M | 7.88% | 2.24% | 0.0% | Q2 2023 | |
| $533M | 5.31% | 7.88% | Not reported | Q3 2019 | |
| $528M | 5.25% | 9.35% | Not reported | Q4 2016 | |
| $518M | 5.16% | 1.15% | +5.3% | Q2 2017 | |
| $473M | 4.70% | 7.94% | +247.1% | Q1 2024 | |
| $347M | 3.45% | 6.29% | +452.5% | Q4 2025 | |
| $278M | 2.77% | 9.23% | +791.9% | Q3 2021 | |
| $261M | 2.60% | 5.20% | +10917.4% | Q4 2025 | |
| $250M | 2.49% | 0.88% | -16.7% | Q3 2015 | |
| $239M | 2.38% | 5.46% | +8.8% | Q4 2023 | |
| $235M | 2.34% | 7.78% | +0.3% | Q4 2020 | |
| ATAPGEApogee Therapeutics, Inc. | $234M | 2.33% | 3.72% | +2.6% | Q3 2023 |
| $210M | 2.09% | 5.29% | Not reported | Q4 2023 | |
| $210M | 2.09% | 3.20% | -28.1% | Q3 2025 | |
| $197M | 1.96% | 5.08% | +41.2% | Q4 2025 | |
| $183M | 1.82% | 9.04% | +1.4% | Q2 2019 | |
| $179M | 1.78% | 2.21% | Not reported | Q3 2020 | |
| $159M | 1.58% | 4.18% | Not reported | Q2 2022 | |
| $151M | 1.50% | 9.04% | +2.6% | Q3 2018 | |
| APAPLSApellis Pharmaceuticals, Inc. | $148M | 1.48% | 2.88% | -51.9% | Q4 2021 |
| $147M | 1.46% | 9.58% | Not reported | Q1 2021 | |
| $142M | 1.41% | 2.14% | +13.4% | Q4 2025 | |
| $140M | 1.39% | 1.06% | Not reported | Q2 2025 | |
| $137M | 1.36% | 1.13% | Not reported | Q3 2020 | |
| $127M | 1.26% | 9.60% | +12.6% | Q3 2020 | |
| $124M | 1.23% | 0.59% | -5.5% | Q4 2024 | |
| $114M | 1.13% | 1.82% | Not reported | Q3 2025 | |
| $101M | 1.01% | 0.06% | +117.3% | Q2 2023 | |
| $101M | 1.00% | 4.10% | Not reported | Q3 2024 | |
| $83.4M | 0.83% | 9.57% | Not reported | Q2 2021 | |
| $81.7M | 0.81% | 9.15% | Not reported | Q3 2024 | |
| $81.7M | 0.81% | 9.33% | Not reported | Q3 2021 | |
| CPCNTACentessa Pharmaceuticals PLC | $81.6M | 0.81% | 1.33% | +14.7% | Q3 2024 |
| $78.9M | 0.79% | 1.56% | 0.0% | Q4 2019 | |
| $76.4M | 0.76% | 3.71% | +21.6% | Q4 2021 | |
| $74.4M | 0.74% | 11.78% | +446.0% | Q4 2025 | |
| $67.7M | 0.67% | 9.10% | +30.4% | Q3 2019 | |
| $63.3M | 0.63% | 16.21% | Not reported | Q1 2018 | |
| $61.2M | 0.61% | 4.76% | -16.6% | Q3 2023 | |
| $59.1M | 0.59% | 1.00% | Not reported | Q3 2023 | |
| $58.8M | 0.59% | 7.88% | +21.4% | Q4 2024 | |
| $56.7M | 0.56% | 2.39% | 0.0% | Q4 2025 | |
| $56.3M | 0.56% | 8.89% | +3.0% | Q2 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $52.7M | 0.52% | 1.38% | +7.4% | Q2 2025 |
| $42.3M | 0.42% | 4.10% | -30.3% | Q4 2017 | |
| $39.3M | 0.39% | 0.85% | New | Q1 2026 | |
| $36.7M | 0.37% | 0.42% | +0.2% | Q4 2014 | |
| $35.3M | 0.35% | 14.17% | Not reported | Q1 2023 | |
| $34.9M | 0.35% | 7.49% | Not reported | Q1 2025 | |
| Q4 2025Reported Feb 17, 202690 positions | |||||
| $1.16B | 11.63% | 8.73% | Not reported | Q2 2023 | |
| $843M | 8.44% | 2.26% | +57.0% | Q2 2023 | |
| $588M | 5.89% | 9.51% | Not reported | Q4 2016 | |
| $566M | 5.67% | 1.09% | Not reported | Q2 2017 | |
| $442M | 4.43% | 8.08% | -12.1% | Q3 2019 | |
| $344M | 3.44% | 1.07% | -25.0% | Q3 2015 | |
| $281M | 2.81% | 5.09% | +39.9% | Q4 2023 | |
| $273M | 2.74% | 7.84% | +5.0% | Q4 2020 | |
| $270M | 2.70% | 4.72% | +119.0% | Q3 2025 | |
| $269M | 2.70% | 2.21% | Not reported | Q4 2020 | |
| $210M | 2.10% | 3.66% | New | Q4 2025 | |
| ATAPGEApogee Therapeutics, Inc. | $205M | 2.05% | 3.97% | Not reported | Q3 2023 |
| APAPLSApellis Pharmaceuticals, Inc. | $193M | 1.93% | 6.05% | Not reported | Q4 2021 |
| $191M | 1.91% | 4.20% | Not reported | Q2 2022 | |
| $189M | 1.89% | 8.83% | Not reported | Q3 2018 | |
| $176M | 1.76% | 9.41% | +8.3% | Q2 2019 | |
| $174M | 1.75% | 1.89% | New | Q4 2025 | |
| $173M | 1.73% | 2.21% | Not reported | Q3 2020 | |
| $169M | 1.69% | 9.61% | Not reported | Q1 2021 | |
| $162M | 1.62% | 1.75% | -20.6% | Q1 2019 | |
| $151M | 1.52% | 1.13% | Not reported | Q3 2020 | |
| $151M | 1.51% | 1.06% | Not reported | Q2 2025 | |
| $137M | 1.37% | 5.34% | +15.2% | Q4 2023 | |
| $123M | 1.23% | 0.63% | +203.7% | Q4 2024 | |
| $120M | 1.20% | 8.53% | +29.7% | Q3 2020 | |
| $114M | 1.15% | 1.82% | +128.9% | Q3 2025 | |
| $106M | 1.07% | 9.40% | Not reported | Q3 2021 | |
| $104M | 1.04% | 9.43% | +8.9% | Q3 2024 | |
| $92.3M | 0.92% | 0.46% | Not reported | Q2 2017 | |
| $90.2M | 0.90% | 5.75% | -32.7% | Q3 2023 | |
| MMASIMasimo Corp | $88.9M | 0.89% | 1.27% | Not reported | Q3 2015 |
| $88.8M | 0.89% | 5.95% | -16.1% | Q4 2017 | |
| $86.1M | 0.86% | 0.06% | -50.0% | Q3 2023 | |
| $83.5M | 0.84% | 2.49% | +18.3% | Q1 2024 | |
| $82.3M | 0.82% | 7.13% | Not reported | Q3 2019 | |
| $80.8M | 0.81% | 1.56% | Not reported | Q4 2019 | |
| $76.2M | 0.76% | 5.64% | -24.2% | Q1 2025 | |
| $75.4M | 0.75% | 9.57% | +6.5% | Q2 2021 | |
| $69.4M | 0.70% | 8.97% | +11.6% | Q2 2024 | |
| $69M | 0.69% | 3.11% | -7.9% | Q4 2021 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $62.9M | 0.63% | 1.41% | +54.9% | Q2 2025 |
| $62.4M | 0.62% | 4.22% | +5.8% | Q3 2024 | |
| $62.1M | 0.62% | 16.33% | Not reported | Q1 2018 | |
| $60.4M | 0.61% | 9.11% | +0.6% | Q4 2024 | |
| $57.3M | 0.57% | 0.03% | -50.0% | Q2 2023 | |
| RTRAPTRAPT Therapeutics, Inc. | $55.5M | 0.56% | 5.91% | +11.3% | Q4 2024 |
| $54.9M | 0.55% | 1.14% | New | Q4 2025 | |
| $50.8M | 0.51% | 8.46% | +21.2% | Q1 2025 | |
| $46.8M | 0.47% | 1.01% | Not reported | Q3 2023 | |
| CPCNTACentessa Pharmaceuticals PLC | $44.8M | 0.45% | 1.20% | -21.9% | Q3 2024 |
| Q3 2025Reported Nov 14, 202574 positions | |||||
| $914M | 11.27% | 8.78% | Not reported | Q2 2023 | |
| $497M | 6.12% | 1.11% | Not reported | Q2 2017 | |
| ABRNAMAvidity Biosciences, Inc. | $496M | 6.11% | 7.75% | +18.2% | Q2 2020 |
| $475M | 5.86% | 9.69% | Not reported | Q4 2016 | |
| $444M | 5.47% | 1.45% | Not reported | Q2 2023 | |
| $382M | 4.71% | 9.22% | Not reported | Q3 2019 | |
| $322M | 3.97% | 1.45% | -22.9% | Q3 2015 | |
| ATAKROAkero Therapeutics, Inc. | $260M | 3.20% | 6.83% | Not reported | Q4 2023 |
| $258M | 3.18% | 7.12% | -14.2% | Q4 2017 | |
| $220M | 2.70% | 2.22% | +0.3% | Q4 2020 | |
| $215M | 2.64% | 3.66% | +4.7% | Q4 2023 | |
| MMRUSMerus N.V. | $191M | 2.35% | 2.67% | -49.4% | Q4 2021 |
| $189M | 2.33% | 7.49% | +2.1% | Q4 2020 | |
| $181M | 2.23% | 0.13% | -17.0% | Q3 2023 | |
| $177M | 2.18% | 9.65% | Not reported | Q1 2021 | |
| $152M | 1.88% | 4.22% | -20.6% | Q2 2022 | |
| $150M | 1.84% | 2.27% | Not reported | Q3 2020 | |
| $149M | 1.84% | 1.07% | Not reported | Q2 2025 | |
| $136M | 1.67% | 2.22% | -26.2% | Q1 2019 | |
| $120M | 1.48% | 9.30% | Not reported | Q2 2019 | |
| ATAPGEApogee Therapeutics, Inc. | $108M | 1.33% | 4.57% | Not reported | Q3 2023 |
| $106M | 1.31% | 8.91% | +0.2% | Q3 2018 | |
| MMASIMasimo Corp | $101M | 1.24% | 1.27% | Not reported | Q3 2015 |
| $98M | 1.21% | 3.38% | +90.8% | Q4 2021 | |
| $92.5M | 1.14% | 1.18% | +72.9% | Q3 2020 | |
| $90.7M | 1.12% | 9.71% | Not reported | Q3 2021 | |
| $90.5M | 1.12% | 0.06% | Not reported | Q2 2023 | |
| $79.6M | 0.98% | 10.70% | +0.5% | Q2 2021 | |
| $79.6M | 0.98% | 8.89% | -2.7% | Q3 2023 | |
| $77.7M | 0.96% | 0.21% | -58.6% | Q4 2024 | |
| $75.1M | 0.93% | 7.25% | +26.5% | Q3 2020 | |
| $73M | 0.90% | 8.72% | +158.9% | Q3 2024 | |
| $68.5M | 0.84% | 2.17% | Not reported | Q1 2024 | |
| $65.6M | 0.81% | 7.50% | Not reported | Q1 2025 | |
| $60.7M | 0.75% | 5.99% | Not reported | Q4 2023 | |
| $57.7M | 0.71% | 16.35% | Not reported | Q1 2018 | |
| CPCNTACentessa Pharmaceuticals PLC | $55.6M | 0.68% | 1.70% | +49.8% | Q3 2024 |
| $50.2M | 0.62% | 1.01% | -64.3% | Q3 2023 | |
| $49.9M | 0.61% | 9.07% | +5.9% | Q4 2024 | |
| $49.8M | 0.61% | 2.48% | New | Q3 2025 | |
| $47.9M | 0.59% | 8.13% | +27.6% | Q1 2025 | |
| $47.6M | 0.59% | 0.22% | -50.0% | Q1 2025 | |
| $40.2M | 0.50% | 3.02% | Not reported | Q1 2024 | |
| RTRAPTRAPT Therapeutics, Inc. | $37.9M | 0.47% | 8.89% | Not reported | Q4 2024 |
| $37.4M | 0.46% | 4.02% | Not reported | Q3 2024 | |
| $36.6M | 0.45% | 2.03% | +71.0% | Q1 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $36.3M | 0.45% | 0.92% | +86.8% | Q2 2025 |
| $34.9M | 0.43% | 5.14% | New | Q3 2025 | |
| $29.7M | 0.37% | 0.55% | New | Q3 2025 | |
| $29.6M | 0.36% | 0.09% | -37.1% | Q1 2025 | |
Premium opens every quarter this fund has filed